Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 98

Doctors Doctor Drugs Manufacturing 98

The Pharma Data

JANUARY 4, 2021

CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumor activity by potentially amplifying the immune response. “We TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. About Tecentriq ® (atezolizumab). About Genentech.

Medicine 52

Medicine Immune Response Protein Gene 52

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 52

Doctors Doctor Drugs Manufacturing 52

The Pharma Data

JANUARY 21, 2021

Doctors need better tools to evaluate the status of COVID-19 patients as early as possible because many of the treatments—such as monoclonal antibodies—are in short supply, and we know that some patients will get better without intensive treatments,” said co-senior author Andrew E. The research was published in the journal JCI Insight.

Research 52

Research DNA Hormones Vaccination 52

pharmaphorum

NOVEMBER 23, 2020

Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available. Doctors now have another option to choose from to combat the disease, following EUAs for drugs such as Eli Lilly’s baricitinib and Gilead’s Veklury (remdesivir).

Antibody 52

Antibody Immune Response Trials Engineer 52

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92